Generic Name: elvitegravir

Pronunciation: vye-TECK-ta

Abbreviation: EVG

Other Market Name: N/A

Drug Class: Integrase Inhibitors

Pharmaceutical Company: Gilead Sciences

Approval Status: Approved

Generic Version Available: No

Experimental Code: GS-9137

Drug Recommendation

Part of a recommended DHHS regimen for treatment-naïve patients.

Visit for the full DHHS guidelines.

General Info

Vitekta is an HIV medication. It is in a category of HIV medicines called integrase inhibitors. Vitekta was approved by the U.S. Food and Drug Administration for use by people living with HIV in September 2014.

Vitekta is available as a single drug or in the fixed-dosed combination drug Stribild.

Vitekta must be used in combination with a Norvir (ritonavir)-boosted protease inhibitor and another HIV drug.


Adult Dose: One 85 mg tablet once a day when taken with twice-daily Kaletra (lopinavir) or once-daily Reyataz (atazanavir)/Norvir (ritonavir)

One 150 mg tablet once a day when taken with twice-daily Lexiva (fosamprenavir)/Norvir (ritonavir), Prezista (darunavir)/Norvir (ritonavir) or Aptivus (tipranavir)/Norvir (ritonavir)

Pediatric Dose: N/A

Dosing Info: Take with food.

Side Effects

The most common side effect of Vitekta is diarrhea.

The risk and severity of other side effects will depend on the other HIV drug components of the regimen used.  

Drug Interactions

For a review of drug interactions, including prescription and over-the-counter medications and supplements that should not be taken with Vitekta or may require dose adjustments, consult the Vitekta package insert:

Other Info

Before taking this medication, tell your doctor if you have kidney disease or liver disease (including hepatitis B. In addition, tell your doctor if you are pregnant or planning to become pregnant, if you are breast feeding, and all your medical conditions, including all prescription and over-the-counter medications and supplements you are taking.

For More Info:

Co-Pay Program Info:

Patient Assistance Program Info:

Last Revised: January 13, 2016